Bio-Gene Technology Ltd (BGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bio-Gene Technology Ltd (BGT) has a cash flow conversion efficiency ratio of -0.811x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-946.61K ≈ $-669.78K USD) by net assets (AU$1.17 Million ≈ $825.57K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bio-Gene Technology Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Bio-Gene Technology Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BGT current and long-term liabilities for a breakdown of total debt and financial obligations.
Bio-Gene Technology Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bio-Gene Technology Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIG Industries Bhd
KLSE:7005
|
-0.091x |
|
Conduit Holdings Ltd
LSE:CRE
|
0.106x |
|
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
|
-0.292x |
|
Avalon Holdings Corporation
NYSE MKT:AWX
|
0.039x |
|
Eddy Smart Home Solutions Ltd
V:EDY
|
0.095x |
|
Star Minerals Ltd
AU:SMS
|
-0.110x |
|
Conquest Resources Ltd
V:CQR
|
-0.100x |
|
Tempo Inti Media Tbk
JK:TMPO
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Bio-Gene Technology Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Bio-Gene Technology Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Bio-Gene Technology Ltd (BGT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.63 Million ≈ $1.15 Million |
AU$-2.54 Million ≈ $-1.80 Million |
-1.563x | -58.38% |
| 2024-06-30 | AU$2.79 Million ≈ $1.97 Million |
AU$-2.75 Million ≈ $-1.95 Million |
-0.987x | +2.98% |
| 2023-06-30 | AU$3.22 Million ≈ $2.28 Million |
AU$-3.28 Million ≈ $-2.32 Million |
-1.017x | -14751.29% |
| 2022-06-30 | AU$6.27 Million ≈ $4.44 Million |
AU$43.52K ≈ $30.79K |
0.007x | +101.61% |
| 2021-06-30 | AU$4.25 Million ≈ $3.00 Million |
AU$-1.83 Million ≈ $-1.29 Million |
-0.430x | -56.90% |
| 2020-06-30 | AU$6.00 Million ≈ $4.25 Million |
AU$-1.64 Million ≈ $-1.16 Million |
-0.274x | +38.40% |
| 2019-06-30 | AU$4.95 Million ≈ $3.50 Million |
AU$-2.20 Million ≈ $-1.56 Million |
-0.445x | -29.44% |
| 2018-06-30 | AU$6.91 Million ≈ $4.89 Million |
AU$-2.37 Million ≈ $-1.68 Million |
-0.344x | -327.50% |
| 2017-06-30 | AU$9.07 Million ≈ $6.42 Million |
AU$-729.15K ≈ $-515.92K |
-0.080x | +90.93% |
| 2016-06-30 | AU$473.35K ≈ $334.92K |
AU$-419.35K ≈ $-296.71K |
-0.886x | -440.17% |
| 2014-06-30 | AU$290.03K ≈ $205.21K |
AU$-47.57K ≈ $-33.66K |
-0.164x | -- |
About Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more